Oncology Round-Up: Prostate Cancer Risk in U.S. Veterans; and More

Gene Expression Profile Predicts Lung Cancer Treatment Response

An article in Thoracic Cancer reported that dual high expression of T cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT) and cluster of differentiation 47 (CD47) was associated with a poor prognosis in patients with lung squamous cell carcinoma (LUSC).

Dr. Dan Elgort, M2GEN: Accelerating the Delivery of Precision Medicine in Oncology

M2GEN, an oncology-focused health information company, is focused on accelerating the delivery of precision medicine to treat different cancers. DocWire News spoke with Dan Elgort, PhD, Chief Data and Analytics Officer for M2GEN. Dr. Elgort spoke about the company’s mission to accelerate drug discovery for cancer patients, and about M2GEN’s exciting partnership with tech giant Microsoft.

Prostate Cancer Risk and in U.S. Veterans with Rheumatoid Arthritis

Patients with rheumatoid arthritis (RA) have been shown to have an increased risk of some cancers, but its impact on prostate cancer risk is unclear, according to Austin M. Wheeler and collaborating researchers. The team examined a cohort of patients in the Veterans Health Administration (VA) and reported that “RA was associated with a modestly increased risk of prostate cancer, but not prostate cancer mortality, after accounting for relevant confounders and several potential sources of bias.”

Colon Cancer Death Rates Are Falling Among the Young — But Only for Whites

A look at colon cancer survival among Americans younger than 50 turned up a glaring discrepancy: Survival five years after diagnosis improved to nearly 70% among white patients over two decades, but was less than 58% among Black patients.

Retinoblastoma Binding Protein Family Related to Triple-Negative Breast Cancer

Recent evidence has suggested that proteins in the Retinoblastoma binding protein (RBBP) family play a functional role in tumor development. Following these findings, Zitong Zheng and colleagues conducted a study to determine the biological role of RBBP4 in triple-negative breast cancer (TNBC) pathogenesis. After their analyses, they concluded that “the inhibition of RBBP4 suppresses the malignant progression of TNBC cells by regulating EMT.”